Comparative Pharmacology
Head-to-head clinical analysis: MOUNJARO versus YEZTUGO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOUNJARO versus YEZTUGO.
MOUNJARO vs YEZTUGO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It activates GIP and GLP-1 receptors, potentiating glucose-dependent insulin secretion from pancreatic beta cells, reducing glucagon secretion, slowing gastric emptying, and promoting satiety via hypothalamic appetite regulation.
Yeztugo (tugofinitib) is a selective inhibitor of fibroblast growth factor receptor (FGFR) 1-4. It binds to the ATP-binding pocket of FGFR kinases, blocking downstream signaling pathways (RAS-MAPK, PI3K-AKT, STAT) involved in cell proliferation and survival.
Subcutaneous injection once weekly. Starting dose: 2.5 mg for 4 weeks, then increase to 5 mg for at least 4 weeks. For additional glycemic control, may increase in 2.5 mg increments after at least 4 weeks on current dose. Maximum dose: 15 mg once weekly.
YEZTUGO is not an approved drug. No standard dosing available.
None Documented
None Documented
Terminal elimination half-life is approximately 5 days (range 4-6 days), supporting once-weekly dosing. Achieves steady-state after 4-5 weeks.
12-15 hours in healthy adults; prolonged to 24-30 hours in moderate hepatic impairment.
Primarily eliminated via proteolytic degradation, with the parent drug not significantly excreted renally or in feces. Small amounts of metabolites may be excreted in urine and feces.
Primarily renal (>90% unchanged) with 5-10% biliary/fecal elimination.
Category C
Category C
Dual GIP/GLP-1 Receptor Agonist
GLP-1 Receptor Agonist